Shanghai Medicilon Inc. (SHA:688202)

China · Delayed Price · Currency is CNY

107.64

+3.68 (3.54%)

At close: Sep 30, 2026

Market Cap	14.16B +62.5%
Revenue (ttm)	1.38B +31.0%
Net Income	-103.33M
EPS	-0.77
Shares Out	131.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,079,061
Open	104.92
Previous Close	103.96
Day's Range	102.38 - 111.17
52-Week Range	50.50 - 120.00
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Shanghai Medicilon

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow chemistry, carbohydrate chemistry, analytical chemical, ADME/DMPK, pharmacology, safety assessment, IND-Enabling studies, and advanced technology service... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2004

Employees 2,780

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688202

Full Company Profile

Financial Performance

In 2025, Shanghai Medicilon's revenue was 1.16 billion, an increase of 12.08% compared to the previous year's 1.04 billion. Losses were -167.83 million, -49.27% less than in 2024.

Financial Statements